Literature DB >> 9355964

Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo.

M W Beilharz1, W McDonald, M W Watson, J Heng, J McGeachie, C M Lawson.   

Abstract

Immunity to viral infections involves both innate and antigen-specific immune responses. The antiviral properties of interferons (IFNs) are part of the innate immune response. Low doses of type I IFNs (IFN-alpha and IFN-beta) administered daily (10 IU per mouse) by the oral route significantly reduced the early replication of murine cytomegalovirus (MCMV) in both the spleen and liver of MCMV-infected susceptible BALB/c mice. Significant inhibition of virus replication was observed for two different inoculum doses of virus (2 x 10(4) pfu per mouse [0.6 LD50] and 2 x 10(4.12) pfu per mouse [0.8 LD50]). Analysis of IFN retention, using [35S]-labeled IFN-alpha1 compared with the nonreceptor binding mutant IFN-alpha1 (R33M) administered orally to mice, revealed binding of wild-type IFN-alpha1 to several tissues. In particular, IFN was retained by tissues proximal to lymphoid regions, including the posterior nasal cavity, posterior tongue, small intestine, and rectum. These findings suggest that type I IFNs may inhibit MCMV replication by distal binding of the orally administered IFN to various tissues, which in turn augment the primary immune response to virus infection.

Entities:  

Mesh:

Year:  1997        PMID: 9355964     DOI: 10.1089/jir.1997.17.625

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Interferon as a Mucosal Adjuvant for an Influenza Vaccine in Pigs.

Authors:  Lirong Liu; Wenhui Fan; He Zhang; Shuang Zhang; Liang Cui; Meng Wang; Xiaoyuan Bai; Wenxian Yang; Lei Sun; Limin Yang; Wenjun Liu; Jing Li
Journal:  Virol Sin       Date:  2019-04-15       Impact factor: 4.327

3.  A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse.

Authors:  Chuan-Mo Lee; Chi-Yi Chen; Rong-Nan Chien; Kuo-Chih Tseng; Cheng-Yuan Peng; Shui-Yi Tung; Yi-Jen Fang; Yi-Hsiang Huang; Sheng-Nan Lu; Chao-Hung Hung; Tsung-Jang Tsai; Chien-Chung Fang; Chao-Wei Hsu; Chau-Ting Yeh
Journal:  J Interferon Cytokine Res       Date:  2013-11-15       Impact factor: 2.607

4.  Reduced interferon (IFN)-α conditioned by IFNA2 (-173) and IFNA8 (-884) haplotypes is associated with enhanced susceptibility to severe malarial anemia and longitudinal all-cause mortality.

Authors:  Prakasha Kempaiah; Samuel B Anyona; Evans Raballah; Gregory C Davenport; Tom Were; James B Hittner; John M Ong'echa; Douglas J Perkins
Journal:  Hum Genet       Date:  2012-05-09       Impact factor: 4.132

Review 5.  Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.

Authors:  Sara Frazzini; Federica Riva; Massimo Amadori
Journal:  Vet Sci       Date:  2021-06-11

6.  Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.

Authors:  Alayne L Bennett; David W Smith; Martin J Cummins; Peter A Jacoby; Joseph M Cummins; Manfred W Beilharz
Journal:  Influenza Other Respir Viruses       Date:  2013-02-09       Impact factor: 4.380

7.  Low-dose oral interferon modulates expression of inflammatory and autoimmune genes in cattle.

Authors:  Stephen W Mamber; Jeremy Lins; Volkan Gurel; David P Hutcheson; Pablo Pinedo; David Bechtol; Steven Krakowka; Rachel Fields-Henderson; Joseph M Cummins
Journal:  Vet Immunol Immunopathol       Date:  2016-03-04       Impact factor: 2.046

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.